2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114628
    MS012 2089617-83-2 98%
    MS012 is a selective GLP inhibitor (IC50=7 nM). MS012 can be used in research of GLP dysregulation, including cancer, inflammatory diseases, and neuroregenerative disorders.
    MS012
  • HY-114678
    LY302148 182564-47-2 98%
    LY302148 is a receptor ligand for 5-HT1F. Compared to the Emax of 5-HT, LY302148 behaves as a partial agonist for the 5-HT1F receptor. In the [35S]GTPγS binding assay targeting human 5-HT1F receptors, LY302148 exhibits good potency with an EC50 value of 5.23 nM. LY302148 can be used in the research of migraine.
    LY302148
  • HY-114692
    Eterobarb 27511-99-5 98%
    Eterobarb (EX 12-095), a barbiturate derivative, is an anticonvulsant agent.
    Eterobarb
  • HY-114705
    Ameltolide 787-93-9
    Ameltolide (LY-201116; ADD 75073) is a novel anticonvulsant agent and can be used for epilepsy research.
    Ameltolide
  • HY-114791
    Lobelanidine 552-72-7 98%
    Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC50 of 2.8 and 8.2 μM.
    Lobelanidine
  • HY-114798
    Rabelomycin 28399-50-0 98%
    Rabelomycin is antibiotic, which exhibits antimicrobial activity against gram positive bacteria. Rabelomycin exhibits inhibitory activity against inducible nitric oxide synthase (iNOS) with an IC50 of 63.9 μM.
    Rabelomycin
  • HY-114803
    Kokusaginine 484-08-2 98%
    Kokusaginine is a furoquinoline alkaloids, which exhibits inhibitory efficacy for acetylcholinesterase (AChE) with an IC50 of 28.2 μM. Kokusaginine exhibits anti-proliferative and apoptotic inducing effects in MCF-7/ADR cells.
    Kokusaginine
  • HY-114871
    SL651498 205881-86-3 98%
    SL651498 is a full agonist of α2 and α3 GABAA receptors, and a partial agonist of α1 and α5 GABAA receptors. SL651498 shows anxiolytic and anticonvulsant activities.
    SL651498
  • HY-114880
    AB-FUBINACA 3-fluorobenzyl isomer 1185282-19-2 98%
    AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (Ki= 0.9 nM), exhibiting anticonvulsant activity.
    AB-FUBINACA 3-fluorobenzyl isomer
  • HY-114883
    Homocarnosine 3650-73-5 98%
    Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects.Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation.
    Homocarnosine
  • HY-114895
    SSR504734 free base 742693-38-5 98%
    SSR504734 free base is an orally active, selective and reversible inhibitor of human, rat, and mouse GlyT1 (IC50=18, 15, and 38 nM, respectively). SSR504734 free base shows anti-schizophrenia, anti-anxiety and anti-depression activities.
    SSR504734 free base
  • HY-114898
    ML404 1826026-00-9 98%
    ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke.
    ML404
  • HY-114899
    Azamethiphos 35575-96-3
    Azamethiphos is an organophosphate insecticide and a neurotoxic agent, causing acetylcholinesterase (AChE) inhibition.
    Azamethiphos
  • HY-114915
    PSB-1434 1619884-65-9 98.05%
    PSB-1434 is an inhibitor for monoamine oxidase B (MAO-B), with an IC50 of 1.59 nM.
    PSB-1434
  • HY-114945
    CGRP antagonist 2 866086-05-7 98%
    CGRP antagonist 2 is a CGRP receptor antagonist. CGRP antagonist 2 can be used for pain relief.
    CGRP antagonist 2
  • HY-114946
    N-methyl-4,4-difluoro Modafinil 1613222-54-0 98%
    N-methyl-4,4-difluoro Modafinil is categorized as a nootropic.
    N-methyl-4,4-difluoro Modafinil
  • HY-114954
    CID1792197 1164479-69-9 98%
    CID1792197 is a GPR55 agonist with an EC50 value of 0.11 μM.
    CID1792197
  • HY-114987
    EMD 21657 61711-37-3 98%
    EMD 21657 is a derivative of Piracetam (HY-B0585). EMD 21657 inhibits LOT compound action potential, and enhances the local anesthetic effect of Hexanol (HY-W032022). EMD 21657 exhibits hemolytic effect, and can be used in research about alcoholic encephalopathy syndrome.
    EMD 21657
  • HY-115004
    MM-433593 1006604-91-6 98%
    MM-433593 is a potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) that is orally administered to inhibit pain, inflammation, and related disorders. Pharmacokinetic studies of MM-433593 in macaques revealed a biphasic elimination profile with a rapid distribution phase and a slower elimination phase, with a systemic clearance of 8-11 mL/min/kg. MM-433593 exhibits moderate oral bioavailability (14-21%) and its metabolism primarily involves oxidation of the methyl group on the indole ring, resulting in a variety of sulfate, glucuronide, or glutathione-conjugated metabolites.
    MM-433593
  • HY-115139
    Fenadiazole 1008-65-7 98%
    Fenadiazole acts as a central nervous system agent to manage insomnia and dreaminess.
    Fenadiazole
Cat. No. Product Name / Synonyms Application Reactivity